Cybin (NASDAQ:HELP) Insider Eric So Purchases 100,000 Shares of Stock

Cybin Inc. (NASDAQ:HELP) insider Eric So acquired 100,000 shares of the firm’s stock in a transaction dated Tuesday, September 8th. The shares were bought at an average cost of $12.39 per share, with a total value of $1,239,000.00. Following the completion of the acquisition, the insider directly owned 4,465,014 shares of the company’s stock, valued at $55,321,523.46. The trade was a 2.29% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link.

Cybin Stock Up 1.0%

Shares of Cybin stock opened at $12.97 on Friday. Cybin Inc. has a twelve month low of $3.76 and a twelve month high of $14.35. The company’s 50 day moving average is $9.97 and its 200 day moving average is $6.89. The company has a market cap of $980.66 million, a price-to-earnings ratio of -4.29 and a beta of 0.63.

Cybin (NASDAQ:HELP) last posted its earnings results on Friday, August 14th. The company reported ($0.91) EPS for the quarter, missing analysts’ consensus estimates of ($0.80) by ($0.11). Sell-side analysts expect that Cybin Inc. will post -2.95 EPS for the current fiscal year.

Wall Street Analyst Weigh In

HELP has been the subject of several research analyst reports. TD Cowen lifted their price objective on Cybin from $8.00 to $62.00 and gave the stock a “buy” rating in a report on Thursday, August 20th. Wells Fargo & Company began coverage on Cybin in a report on Monday, July 27th. They issued an “overweight” rating and a $16.00 target price on the stock. Finally, Wall Street Zen raised Cybin from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 29th. Five research analysts have rated the stock with a Buy rating, According to MarketBeat.com, Cybin currently has a consensus rating of “Buy” and an average price target of $48.60.

Institutional Trading of Cybin

Several hedge funds have recently bought and sold shares of HELP. Millennium Management LLC increased its position in Cybin by 1,388.5% in the fourth quarter. Millennium Management LLC now owns 1,028,549 shares of the company’s stock worth $8,414,000 after buying an additional 959,448 shares in the last quarter. Pale Fire Capital SE purchased a new position in shares of Cybin during the 2nd quarter valued at about $1,015,000. Bank of America Corp DE lifted its position in shares of Cybin by 66.8% during the 2nd quarter. Bank of America Corp DE now owns 29,443 shares of the company’s stock valued at $247,000 after buying an additional 11,790 shares in the last quarter. AXQ Capital LP bought a new position in shares of Cybin during the 2nd quarter valued at approximately $75,000. Finally, Osaic Holdings Inc. grew its stake in shares of Cybin by 46.7% during the 2nd quarter. Osaic Holdings Inc. now owns 7,543 shares of the company’s stock valued at $63,000 after acquiring an additional 2,400 shares during the period. Institutional investors own 17.94% of the company’s stock.

Key Cybin News

Here are the key news stories impacting Cybin this week:

• Positive Sentiment: Insider Paul Glavine bought 100,000 shares for approximately $1.25 million on September 8, increasing his direct ownership by 2.40%. Insider Eric H. L. So also purchased 100,000 shares for about $1.24 million, lifting his stake by 2.29%. These transactions follow additional purchases by both insiders in late August and early September, representing a notable pattern of open-market buying and likely supporting investor confidence. Eric So SEC filing Paul Glavine SEC filing
• Positive Sentiment: Cybin’s commercial operations are scheduled to receive investor exposure at the Morgan Stanley 24th Annual Global Healthcare Conference on September 16. CEO Michael Halstead is expected to participate in a fireside chat, potentially providing updates on the company’s psychedelic-based mental-health drug pipeline. Morgan Stanley conference announcement
• Neutral Sentiment: Reported short interest was zero shares with a zero-day days-to-cover ratio. However, the filing also showed an invalid “NaN” percentage change, making the data unreliable as an indicator of short-selling pressure.
• Negative Sentiment: Cybin remains an unprofitable clinical-stage biotechnology company. Its latest quarterly loss of $0.91 per share was worse than the expected $0.80 loss, and analysts project a full-year loss of approximately $2.95 per share. With no new trial result or regulatory approval reported, valuation and future financing needs remain important risks after the stock’s sharp advance.

About Cybin

Cybin Inc is a clinical-stage biopharmaceutical company focused on the development of psychedelic-based therapeutics for the treatment of mental health disorders. Headquartered in Toronto and listed on the NASDAQ under the symbol HELP, Cybin pursues research and development programs intended to harness the therapeutic potential of psychedelic compounds to address conditions with significant unmet need.

The company operates a drug discovery and development platform aimed at creating novel small-molecule psychedelic analogs and tailored formulations.